The Institute for Clinical and Economic Review, which receives support from insurance companies, has begun its financial analysis of how two new SCD treatments, crizanlizumab and voxelotor, will affect insurance profits.
SSTs are considered game changers in medicine with the potential to cure rare, fatal or chronic diseases, such as Alzheimer’s disease.
Massachusetts state representatives, have introduced legislation that would block insurance companies, hospitals, health maintenance organizations, and the state’s Medicaid program, MassHealth, from using “quality-adjusted life years” in providing care to patients.
The Institute for Clinical and Economic Review will conduct an insurance profit analysis for two new additive therapies cardiovascular disease.
Their kids have a rare and fatal disease. ICER President Dr. Steve Pearson believes Duchenne moms shouldn't get a "vote" on their kids' treatment.
ICER. What is it? Who is it? Who put them in charge of my children’s health care? I ask this question – urgently – because Thursday, this group called ICER…
Citing its impact on “health care insurance costs,” the Institute for Clinical and Economic Review has issued its dreaded insurance profitability “alert” for two new treatments for peanut allergies. ICER’s report encourages insurance companies to deny coverage and impose substantial barriers for patients seeking access to the treatments.
July is the month where we as a nation commemorate the Declaration of Independence of our country. On July 4, 1776 the Continental Congress declared that the thirteen American Colonies…
ICER uses quality-adjusted life years to calculate value and determine health care access. Here are 5 ways that the QALY formula is bad for patients.
The Institute for Clinical and Economic Review and its controversial “one-size-fits-all” value framework are a direct threat to patients living with rare diseases, an independent report warns.